Document:

Exhibit
10.34

 

CONSULTING
SERVICES AGREEMENT

 

 

 

This
Consulting Services Agreement (the “Agreement”), dated December 1, 2019, is entered into between Pamela Marrone
(“Consultant”) and Marrone Bio Innovations, Inc., a Delaware corporation (the “Company”).

 

WHEREAS,
for the parties’ mutual benefit, following Consultant’s retirement from service as an employee and Chief Executive
Officer of the Company pursuant to that certain Employment Separation Agreement, dated as of December 1, 2019, by and between
Consultant and the Company (the “Separation Agreement”), the Company would like to engage the services of Consultant,
and Consultant would like to provide consulting services to the Company on the terms set forth below.

 

NOW,
THEREFORE, in consideration of the mutual covenants and premises set forth in this agreement, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Consultant agree as follows:

 

1.
CONSULTING SERVICES.

 

a.
Term. The term of Consultant’s service as a consultant to the Company will commence on the day immediately
following the Retirement Date (as defined in the Separation Agreement), and will continue for a term of three years thereafter,
unless terminated earlier as set forth below, or extended by mutual agreement of the Company and the Consultant (the “Consulting
Period”).

 

b.
Services. Consultant agrees to provide consulting services to the Company as requested by the Chief Executive Officer
from time to time during the Consulting Period and reporting to the Chief Executive Officer (the “Services”).
The scope, timing and other terms of the Services and related deliverables will be as mutually agreed to between Consultant and
the Company’s Chief Executive Officer from time to time, each in their sole discretion, but initially such Services shall
be as set forth on Exhibit A. Participation in internal meetings at the Company or any subsidiaries or other affiliates (other
than meetings of the Company’s Board of Directors (the “Board”) or any committee’s thereof in which
Consultant is a member) will be by invitation only. During the Consulting Period, Consultant will have the title of Founder.

 

2.
CONSULTING FEES.

 

a. Monthly
Consulting Fees. Subject to Consultant’s satisfactory provision of the consulting services during the
Consulting Period, Consultant will be paid a consulting fee of $19,583.33 per month (the “Monthly Consulting
Fees”), in arrears commencing the month after the Retirement Date.

 

    	 	1	 

    	 

    

 

b.
RSU Grant. Additionally, as consideration for Consultant’s provision of consulting services during the Consulting
Period, subject to approval by the Board, the Company will grant Consultant 1,250,000 restricted stock units (the “RSUs”)
under the Company’s 2013 Stock Incentive Plan, as amended (the “Plan”), as soon as practicable after
the Retirement Date. The RSUs will vest in 1/3 installments on each of the first three anniversaries of the Retirement Date, subject
to Consultant’s “Continuous Service” (as that term is defined in the Plan, except that solely with respect to
the RSUs described in this paragraph, Consultant’s continued service as a Board director without continued service as a
consultant shall not be deemed “Continuous Service”) through the applicable vesting dates. The RSUs will be granted
pursuant to the Company’s standard form of time-vesting RSU agreement, provided that the RSUs will settle immediately upon
vesting.

 

c.
Expenses. Travel expenses reasonably incurred by Consultant directly relating to Consultant’s provision of
consulting services during the Consulting Period are eligible for reimbursement by the appropriate affiliate with respect to which
the consulting services are being performed; provided that such travel expenses are pre-approved by the Company (acting
through its Chief Executive Officer) and within the scope of agreed upon consulting activities; and further provided that such
expenses are reasonable, properly documented and otherwise in accordance with Company policies for travel expense reimbursement.

 

d.
No Other Benefits. During the Consulting Period, Consultant will not be eligible to participate in any vacation,
group medical or life insurance, disability, profit sharing or retirement plans (other than with respect to vested benefits as
of the Retirement Date, including the COBRA benefits described in the Separation Agreement), or any other fringe benefits or benefit
plans offered by the Company to its employees, nor will Consultant be provided an office or office support other than for processing
of expenses.

 

3.
TERMINATION

 

a.
Termination Event under Separation Agreement. Unless explicitly waived by the Company, this Agreement (and the Consulting
Period, if already commenced) shall terminate automatically if there shall have been a Termination Event (as defined in the Separation
Agreement).

 

b.
Termination on Notice. The Consultant may terminate the Consulting Period prior to the third anniversary of the
Retirement Date by providing not less than thirty (30) days advance written notice. The Company may not terminate the Consulting
Period or this Agreement except pursuant to Sections 3(a), 3(c), 3(d), 3(e) or 3(f).

 

    	 	2	 

    	 

    

 

c.
Termination in Connection with Change in Control. The Company may terminate the Consulting Period within eighteen
(18) months of the date on which the Company shall have completed a Change in Control, where “Change in Control”
shall mean any of the following transactions, provided, however, that the Company shall determine under parts (iii) and (iv) whether
multiple transactions are related, and its determination shall be final, binding and conclusive: (i) a merger or consolidation
in which the Company is not the surviving entity, except for a transaction the principal purpose of which is to change the state
in which the Company is incorporated; (ii) the sale, transfer or other disposition of all or substantially all of the assets of
the Company; (iii) any reverse merger or series of related transactions culminating in a reverse merger (including, but not limited
to, a tender offer followed by a reverse merger) in which the Company is the surviving entity but (A) the shares of Company common
stock outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether
in the form of securities, cash or otherwise, or (B) in which securities possessing more than fifty percent (50%) of the total
combined voting power of the Company’s outstanding securities are transferred to a person or persons different from those
who held such securities immediately prior to such merger or the initial transaction culminating in such merger, but excluding
any such transaction or series of related transactions that the Company determines shall not be a Change in Control; (iv) acquisition
in a single or series of related transactions by any person or related group of persons (other than the Company or by a Company-sponsored
employee benefit plan) of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing
more than fifty percent (50%) of the total combined voting power of the Company’s outstanding securities but excluding any
such transaction or series of related transactions that the Company determines shall not be a Change in Control; provided that
any such transaction must also constitute a “change in the ownership or effective control, or in the ownership of a substantial
portion of the assets” (as defined in Section 409A) of the Company.

 

d.
Default or Breach. If either party defaults in the performance of this Agreement or the Separation Agreement, or
materially breaches any of their respective provisions, the non-breaching party may terminate this Agreement (and the Consulting
Period, if then commenced) by giving written notification to the breaching party. Such termination will be effective fifteen days
after written notification is provided to the breaching party unless such breach is unable to be cured, in which case no fifteen
day notice period shall be required. For purposes of this section, material breach of this Agreement includes, but is not limited
to the following: (i) failure of Consultant to materially provide the Services following the commencement of the Consulting Period,
(ii) failure of the Company to pay for Consultant’s Services within sixty (60) days after receipt of Consultant’s
written demand for payment when due, or (iii) any failure of Consultant, whether due to bad faith, negligence or otherwise, to
comply with Section 1(d) of the Separation Agreement or Section 9(c) of this Agreement regarding Company representation, Section
6 of this Agreement regarding confidential information, or Section 8 of this Agreement regarding non-solicitation.

 

e.
Duty of Loyalty. The Company may terminate the Consulting Period immediately if, during the Consulting Period, and
during such time as Consultant remains in service as a member of the Board, without the prior written consent of the Company,
Consultant performs services for any business operating in the biological agricultural products space, other than the Company
or its affiliates, or Ospraie Management, LLC (“Ospraie”) or its affiliates (a “Biologicals Business”),
provided that the Company’s consent is not to be unreasonably withheld if such business is not competitive with the Company
and Consultant’s service to such business would not be inconsistent with her duty of loyalty to the Company. For the purposes
of this Section 3(e), the Company hereby consents to Consultant’s continued service as an advisor to Pheronym, Inc. (provided
there are no material changes to the scope of such services), as well as her performance of services for any educational or other
charitable nonprofit institutions, any mutual benefit organizations in which the Company is a member, for any industry research
organizations and for any institutional, private equity, venture capital, sovereign wealth or other financial investor, including
Ospraie and its affiliates (but not for any strategic or corporate investor and not for any subsidiary, portfolio company or other
investee of any of the foregoing operating in the biological agricultural products space).

 

    	 	3	 

    	 

    

 

f. Other
Termination Grounds. The Company may terminate the Consulting Period immediately if the Consultant has (i) (x)
committed a material breach of any surviving terms of the Employee Confidential Information and Assignment of Inventions
Agreement between the Consultant and the Company (the “Inventions and Restrictive Covenant Agreement”) or
any other material written policy of the Company, or (y) negligently or in bad faith breached the surviving terms of the
Inventions and Restrictive Covenant Agreement, whether or not such breach is material, in each case which breach is not cured
to the satisfaction of the Chief Executive Officer within fifteen days after written notice of such breach is provided to the
Consultant from the Chief Executive Officer (unless the Chief Executive Officer determines that such breach is unable to be
cured, in which case no fifteen day notice period shall be required), (ii) been indicted for any felony or convicted of a
crime involving dishonesty or physical harm to any person, (iii) engaged in dishonesty, unethical conduct, gross negligence
or willful misconduct in the performance of her duties to the Company which has resulted in, or is reasonably expected to
result in, material injury to the business or reputation of the Company, (iv) engaged in conduct which constitutes a material
violation of federal or state law relating to the Company or its business, (v) misappropriated assets of the Company or
(viii) been under the influence of alcohol or illegal drugs (or has engaged in abusive use of legal drugs) in performing the
Services.

 

g.
Effect of Termination. If this Agreement becomes automatically terminated pursuant to Section 3(a), the Consulting
Period will not commence or, if commenced, will automatically terminate, the Parties will have no rights or obligations under
Section 1, and all of Consultant’s then-unvested RSUs and all of Consultant’s unexercised stock options (whether or
not vested) will immediately be forfeited and Consultant will have no further rights with respect to such awards. If Consultant
terminates the Consulting Period pursuant to Section 3(b), Consultant will not be entitled to any further Monthly Consulting Fees,
all of Consultant’s unvested RSUs granted pursuant to Section 2(b) of this Agreement will immediately be forfeited, and
the treatment of Consultant’s other equity awards will be governed by the terms of the applicable award agreement and plan
pursuant to which the restricted stock units and other equity awards were granted, with no accelerated vesting due to the termination.
If the Company terminates this Agreement pursuant to Section 3(c), or if Consultant terminates the Consulting Period pursuant
to Section 3(d), Consultant will receive a lump sum payment within sixty (60) days of such event equal to the sum of the then
remaining Monthly Consulting Fees payable under this Agreement through the third anniversary of the Retirement Date and all of
Consultant’s unvested RSUs granted pursuant to Section 2(b) of this Agreement will become immediately vested and settle
and her vested stock options shall remain outstanding and be exercisable via cashless “net exercise” until three months
after the later of (i) Consultant’s termination of service as a director and (ii) the third anniversary of the Retirement
Date. If the Company terminates the Consulting Period pursuant to Section 3(d) or Section 3(f), Consultant will not be entitled
to any further Monthly Consulting Fees, all of Consultant’s unvested RSUs granted pursuant to Section 2(b) of this Agreement
and all of Consultant’s unexercised stock options (whether or not vested) will immediately be forfeited and Consultant will
have no further rights with respect to such awards. If the Company terminates the Consulting Period pursuant to Section 3(e),
Consultant will not be entitled to any further Monthly Consulting Fees, and all of Consultant’s unvested RSUs granted pursuant
to Section 2(b) of this Agreement will immediately be forfeited and Consultant will have no further rights with respect to such
awards, and all of Consultant’s unvested stock options will immediately cease vesting and shall terminate within 90 days
of the termination of the Consulting Period. The provisions of Sections 3 through 17 of this Agreement shall survive any termination
of the Consulting Period or this Agreement.

 

    	 	4	 

    	 

    

 

4.
RELATIONSHIP OF THE PARTIES AND CONSULTANT COVENANTS.

 

a.
Independent Contractor Status. Consultant will perform the Services as an independent contractor (not an employee).
During the Consulting Period, Consultant shall not have, nor shall Consultant hold herself out as having, any authority to create
any contract or obligation, express or implied, which is binding upon the Company. Consultant agrees that she will not at any
time, before any court, tribunal, administrative body or governmental agency or authority, assert or attempt to assert an employment
relationship with the Company following the Retirement Date.

 

b.
Standard of Care. Consultant shall comply with all applicable laws in connection with or related to the performance
of the Services, and will perform the Services professionally and with due care.

 

5.
DEFENSE AND INDEMNITY.

 

a.
Indemnification of Company by Consultant. Consultant agrees to indemnify, defend, and hold harmless the Company,
and the Company’s officers, directors, employees and shareholders, from and against any and all claims, demands, losses,
costs, expenses, obligations, liabilities, damages, recoveries, and deficiencies, including interest, penalties, and reasonable
attorney fees and costs (collectively, “Claims”), that the Company may incur or suffer that result from, or
are related to, any breach or failure of Consultant to perform any of the covenants, representations, warranties, and agreements
in this Agreement.

 

b.
Indemnification of Consultant by Company. The Company agrees to indemnify, defend, and hold harmless the Consultant
from and against any and all Claims that Consultant may incur or suffer arising from the performance of any Services requested
by the Chief Executive Officer of the Company, except to the extent arising from Consultant’s gross negligence, reckless
or willful misconduct, or breach or failure to perform any of the covenants, representations, warranties, and agreements in this
Agreement.

 

    	 	5	 

    	 

    

 

6.
CONFIDENTIAL INFORMATION.

 

a.
Confidentiality; Limited Use. Consultant acknowledges that she is presently in possession of Confidential Information
of the Company, and that the Company and its affiliates may disclose Confidential Information to Consultant to enable her to perform
the Services. Consultant agrees that, except as required by law, regulatory directive, or judicial order, she will not, without
the prior written consent of the Company, during the Consulting Period or at any time thereafter, disclose or permit to be disclosed
to any third party by any method whatsoever any Confidential Information of the Company or any of its affiliates, or use, lecture
upon or publish any of the Confidential Information, except to the extent such disclosure, use or publication may be required
in direct connection with Consultant’s performing requested Services for the Company or is expressly authorized in writing
by the Chief Executive Officer of the Company. In addition, Consultant understands that the Company has received and in the future
will receive from third parties confidential or Confidential Information (“Third Party Information”) subject
to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited
purposes. During the Consulting Period and thereafter, Consultant will hold Third Party Information in the strictest confidence
and will not disclose or use Third Party Information, except in connection with Consultant’s performing requested Services
for the Company, or as expressly authorized in writing by the Chief Executive Officer of the Company. For purposes of this Agreement,
“Confidential Information” shall include, but not be limited to, any and all trade secrets, records, notes,
memoranda, data, ideas, processes, methods, techniques, systems, formulas, patents, models, devices, programs, computer software,
writings, research, personnel information, customer information, or financial information of the Company or any of its affiliates,
plans, or any other information of whatever nature in the possession or control of the Company which has not been published or
disclosed to the general public (other than by acts of Consultant or her agents in violation of this Agreement), or which gives
to the Company or any of its affiliates an opportunity to obtain an advantage over competitors who do not know of or use it.

 

b.
No Improper Use of Materials. Consultant agrees not to bring to the Company or to use in the performance of Services
for the Company any materials or documents obtained by Consultant from a third party under a binder of confidentiality, unless
such materials or documents are generally available to the public or Consultant has authorization from such third party for the
possession and unrestricted use of such materials.

 

c.
Return of Property. Upon termination of the Consulting Period for any reason, Consultant shall be obligated to promptly
return to the Company—and not retain any copies of—all the Company property, including, without limitation, all documents
and data in whatever form maintained, Confidential Information, Third Party Information, computer hardware or software, files,
papers, memoranda, correspondence, client lists, employee information, financial records and information, credit cards, keys,
access cards, tape recordings, pictures and any other items of any nature which were or are the property of the Company (provided
that Consultant will be permitted to keep her Company-issued cell phone, cell phone number, laptop and iPad).

 

    	 	6	 

    	 

    

 

7.
ASSIGNMENT OF INTELLECTUAL PROPERTY.

 

a.
Inventions. Consultant agrees that any and all ideas, inventions, discoveries, improvements, know-how and techniques
that the Consultant conceives, reduces to practice or develops (a) during the Consulting Period, alone or in conjunction with
others, during or as a result of specifically in connection with and pertinent to performing the Services for the Company under
this Agreement or (b) if arising out of access or use to, or based in whole or in part on, Confidential Information, after termination
of the Consulting Period (collectively, the “Inventions”) shall be the sole and exclusive property of the Company.

 

b.
Unrelated Inventions. For the avoidance of doubt, Inventions shall not include any Inventions that do not principally
relate to the Company’s business, expertise and skills and that can be used, subject to Sections 6, 8 and 9(a) hereof, in
other contexts without negative impact on the Company’s business or operations (“Unrelated Inventions”),
provided that Consultant agrees that if, in the course of performing the Services, Consultant incorporates into any Unrelated
Invention developed under this Agreement, Consultant hereby grants the Company a perpetual, irrevocable, fully paid-up, royalty-free,
transferable, sublicensable (through multiple levels of sublicensees), worldwide right and license to reproduce, distribute, display
and perform (whether publicly or otherwise), prepare derivative works of and otherwise modify, make, have made, sell, offer to
sell, import and otherwise use and exploit (and have others exercise such rights on behalf of the Company) all or any portion
of such Unrelated Invention in connection with developing, enhancing, marketing, distributing or providing, maintaining or supporting,
or otherwise using or exploiting, Company products and services, in any form or media (now known or later developed), without
any obligation to account to Consultant or any third party.

 

c.
Assignment. Consultant hereby assigns and agrees to assign to the Company to the fullest extent permitted by law
all right, title and interest in and to all Inventions. Consultant hereby designates the Company as her agent for, and grants
to the Company a power of attorney with full power of substitution, which power of attorney shall be deemed coupled with an interest,
solely for the purpose of effecting the foregoing assignments from the Consultant to the Company.

 

d.
Cooperation. Consultant further agrees to cooperate and provide reasonable assistance to the Company to obtain and
from time to time enforce United States and foreign patents, copyrights, and other rights and protections claiming, covering or
relating to the Inventions in any and all countries including, without limitation,

 

i.
promptly notifying the Company in writing of full details of any Inventions in particular to enable Company to file for patent
rights with the earliest possible priority date;

 

ii.
doing all such acts and things and sign all such deeds and documents as may be necessary to vest full right, title and interest
in and to any Inventions;

 

    	 	7	 

    	 

    

 

iii.
not to registering nor attempting to register any registerable rights in the Confidential Information or Inventions unless requested
to do so by Company; and

 

iv.
keeping proper notes and records of the conception or generation of any Confidential Information or Inventions.

 

e.
Publications. Consultant agrees to submit to the Company any proposed publication that contains any discussion relating
to the Company’s Confidential Information, Inventions or work performed by Consultant for the Company hereunder. Consultant
further agrees that no such publication shall be made without the prior written consent of the Company, which consent shall not
be unreasonably withheld. Any such consent shall be given with sixty (60) days.

 

f.
Full and Adequate Consideration. Consultant acknowledges that no further remuneration or compensation other than
that provided for in this Agreement is or may become due to Consultant in respect of the performance of the obligations under
this Section 7.

 

8.
NON-SOLICITATION. Consultant agrees that, during the period commencing on the Effective Date and ending on the later of (i)
the termination of the Consulting Period and (ii) the termination of Consultant’s service as a Board director, Consultant
shall not, in any capacity, whether for her own account or on behalf of any other person or organization, directly or indirectly,
with or without compensation, (A) solicit, divert or encourage any officers, directors, employees, agents, consultants or representatives
of the Company (including any subsidiary or other affiliate), to terminate his, her or its relationship with the Company (including
any subsidiary or other affiliate), (B) hire any such officer, director, employee, consultant or representative so solicited,
diverted or encouraged, or (C) solicit, divert or encourage any officers, directors, employees, agents, consultants or representatives
of the Company (including any subsidiary or other affiliate) to become officers, directors, employees, agents, consultants or
representatives of another business, enterprise or entity; provided, that solicitations incidental to general advertising or other
general solicitations in the ordinary course not specifically targeted at such persons and employment of any person not otherwise
solicited in violation hereof shall not be considered a violation of this Section 8. In addition, Consultant shall not be in violation
of this Section 8 solely by providing a reference for a former employee of the Company.

 

9.
OTHER OBLIGATIONS.

 

a.
No Conflicts. Consultant represents that her performance of all of the terms of this Agreement and the performing
of the Services for the Company do not and will not breach or conflict with any agreement with a third party, including an agreement
to keep in confidence any Confidential Information (defined below) of another entity acquired by Consultant in confidence or in
trust prior to the date of this Agreement. Consultant hereby agrees not to enter into any agreement that conflicts with this Agreement,
and, in order to enable the Company to confirm and monitor compliance with the terms of this Section 9(a), the other terms of
this Agreement and the surviving terms of the Inventions and Restrictive Covenants Agreement, Consultant agrees to provide the
Company with fifteen (15) days’ notice prior to performing, or entering into an agreement to perform, services for any Biologicals
Business.

 

    	 	8	 

    	 

    

 

b.
Litigation Cooperation. Consultant agrees that Consultant will cooperate fully with the Company in connection with
any existing or future litigation involving the Company, whether administrative, civil or criminal in nature, in which and to
the extent the Company deems Consultant’s cooperation necessary. The Company shall pay all reasonable, documented travel
and other expenses incurred by the Consultant in connection therewith as long as such expenses and costs are approved in advance
in writing by the Company.

 

c.
No Representation of Company. With the exception of the duties and responsibilities set forth in this Agreement
and Consultant’s duties and responsibilities as a member of the Board, Consultant acknowledges and agrees that will not
have the authority to bind the Company or any of its subsidiaries or other affiliates.

 

10.
ENTIRE AGREEMENT. The Company and Consultant each represents and warrants that no promise or inducement has been offered or
made except as herein set forth and that the consideration stated herein is the sole consideration for this Agreement. This Agreement
(including the exhibits hereto) constitute the complete and entire agreement, and states fully all agreements, understandings,
promises and commitments between the Company and Consultant relating to the subject matter hereof. This Agreement supersedes and
cancels any and all other negotiations, understandings and agreements, oral or written, respecting the subject matter hereof,
including, without limitation, any offer letters, change in control agreements or other employment agreements between Consultant
and the Company or any of its subsidiaries or other affiliates (other than the Inventions and Restrictive Covenant Agreement,
which remains in full force and effect to the extent by its terms it survives termination of Consultant’s employment, and
other than the third sentence of Paragraph 8(a) of the Inventions and Restrictive Covenant Agreement, which the Company hereby
waives), provided, for the avoidance of doubt, that this Agreement does not supersede or cancel the Separation Agreement. This
Agreement may not be modified except by an instrument in writing signed by the party against whom the enforcement of any waiver,
change, modification, or discharge is sought.

 

11.
ASSIGNABILITY; SUCCESSORS; GOVERNING LAW. This Agreement is personal to Consultant, and Consultant may not assign, pledge,
delegate or otherwise transfer to any person or entity any of Consultant’s rights, obligations or duties under this Agreement.
Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise)
to all or substantially all of the Company’s business and/or assets will assume the obligations under this Agreement to
the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes
under this Agreement, the term “Company” will include any successor to the Company’s business and/or assets,
regardless of whether such party executes and delivers any assumption agreement, or any other successor that becomes bound by
the terms of this Agreement by operation of law. This Agreement shall be governed by, construed in accordance with, and enforced
pursuant to the laws of the State of California without regard to principles of conflict of laws. Consultant consents to venue
and personal jurisdiction in the appropriate state of federal court in California for disputes arising under this Agreement.

 

    	 	9	 

    	 

    

 

12.
ENFORCEABILITY. Each of the covenants and agreements set forth in this Agreement are separate and independent covenants, each
of which has been separately bargained for and the parties hereto intend that the provisions of each such covenant shall be enforced
to the fullest extent permissible. Should the whole or any part or provision of any such separate covenant be held or declared
invalid, such invalidity shall not in any way affect the validity of any other such covenant or of any part or provision of the
same covenant not also held or declared invalid. If any covenant shall be found to be invalid but would be valid if some part
thereof were deleted or the period or area of application reduced, then such covenant shall apply with such minimum modification
as may be necessary to make it valid and effective. The failure of either party at any time to require performance by the other
party of any provision hereunder will in no way affect the right of that party thereafter to enforce the same, nor will it affect
any other party’s right to enforce the same, or to enforce any of the other provisions in this Agreement; nor will the waiver
by either party of the breach of any provision hereof be taken or held to be a waiver of any prior or subsequent breach of such
provision or as a waiver of the provision itself.

 

13.
ARBITRATION. The Company and Consultant each agrees that any and all disputes arising out of the terms of this Agreement and
any of the matters herein released, will be subject to binding arbitration. In the event of a dispute, the parties (or their legal
representatives) will promptly confer to select a single arbitrator mutually acceptable to both parties. If the parties cannot
agree on an arbitrator, then the moving party may file a demand for arbitration with the Judicial Arbitration and Mediation Services
(“JAMS”) in San Francisco County, California, who will be selected and appointed consistent with the Comprehensive
Arbitration Rules and Procedures of JAMS (the “JAMS Rules”). Any arbitration will be conducted in a manner
consistent with the JAMS Rules, supplemented by the California Rules of Civil Procedure. The parties further agree that the prevailing
party in any arbitration will be entitled to injunctive relief in any court of competent jurisdiction to enforce the arbitration
award. The parties hereby agree to waive their right to have any dispute between them resolved in a court of law by a judge or
jury. This paragraph will not prevent either party from seeking provisional relief (including a temporary restraining order or
preliminary injunction) from any court having jurisdiction over the parties and the subject matter of their dispute relating to
Consultant’s obligations under this Agreement and the Company’s form of confidential information agreement.

 

14.
COUNTERPARTS. This Agreement may be executed in counterparts, each of which together constitute one and the same instrument.
Signatures delivered by facsimile or email PDF shall be effective for all purposes.

 

15.
NOTICES. Notices and all other communications contemplated by this Agreement will be in writing and will be deemed to have
been duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage
prepaid. In the case of Consultant, mailed notices will be addressed to her at the home address which she most recently communicated
to the Company in writing. In the case of the Company, mailed notices will be addressed to its corporate headquarters, and all
notices will be directed to the attention of the Company’s Chief Executive Officer or General Counsel.

 

    	 	10	 

    	 

    

 

16.
NO CONSTRUCTION AGAINST DRAFTER. No provision of this Agreement or any related document will be construed against or interpreted
to the disadvantage of any party hereto by any court or other governmental or judicial authority by reason of such party having
or being deemed to have structured or drafted such provision.

 

17.
TAXES.

 

a.
Notwithstanding anything to the contrary in this Agreement, the Company may withhold from all amounts payable under this Agreement
all federal, state, local and foreign taxes that are required to be withheld pursuant to any applicable laws and regulations;
however, the Company will not be responsible for withholding or paying any income, payroll, or other applicable taxes, making
any insurance contributions, including for unemployment or disability, or obtaining workers’ compensation insurance on Consultant’s
behalf with respect to any compensation or benefits provided for Consultant’s services as a consultant. Notwithstanding
the foregoing, Consultant shall be responsible for the payment of Consultant’s portion of any and all required federal,
state, local and foreign taxes incurred, or to be incurred, in connection with any amounts payable to Consultant under this Agreement,
and in no event will Consultant be entitled to any reimbursement, gross-up, indemnification or other reimbursement for any taxes
Consultant may incur under this Agreement or otherwise in connection with services provided to the Company or any subsidiary or
other affiliate thereof.

 

b.
Notwithstanding anything to the contrary in this Agreement:

 

i.
Consultant and the Company agree that this Agreement shall be interpreted to comply with or be exempt from Section 409A of the
Internal Revenue Code of 1986, as amended, and the regulations and authoritative guidance promulgated thereunder to the extent
applicable (collectively “Section 409A”), and all provisions of this Agreement shall be construed in a manner
consistent with the requirements for avoiding taxes or penalties under Section 409A. However, the Company makes no representation
that any or all of the payments described in this Agreement will be exempt from or comply with Section 409A and makes no undertaking
to preclude Section 409A from applying to any such payment. Consultant understands and agrees that Consultant shall be solely
responsible for the payment of any taxes, penalties, interest or other expenses incurred by Consultant on account of noncompliance
with Section 409A and in no event will the Company, any of its subsidiaries or other affiliates, or any of their respective directors,
officers, agents, attorneys, employees, executives, shareholders, investors, members, managers, trustees, fiduciaries, representatives,
principals, accountants, insurers, successors or assigns be liable for any additional tax, interest or penalties that may be imposed
on the Consultant under Section 409A or any damages for failing to comply with Section 409A.

 

ii.
Payments pursuant to this Agreement are intended to constitute separate payments for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i)
and Monthly Consulting Fee payments pursuant to Section 2(a) of this Agreement are intended to constitute a series of separate
payments for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii). All reimbursements for costs and expenses under this
Agreement shall be paid in no event later than the end of the calendar year following the calendar year in which the Consultant
incurs such expense. With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits,
except as permitted by Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or
exchange for another benefit, and (ii) the amount of expenses eligible for reimbursements or in-kind, benefits provided during
any taxable year shall not affect the expenses eligible for reimbursement or in-kind benefits to be provided in any other taxable
year.

 

[Signatures
appear on following page]

 

    	 	11	 

    	 

    

 

The
parties have duly executed this Consulting Services Agreement as of the date first written above.

 

	 	MARRONE
    BIO INNOVATIONS, INC.
	 	 	 
	 	By	/s/
    Robert Woods 
	 	Name:
    	Robert
    Woods
	 	Title:
    	Chairman
    of the Board

 

	 	CONSULTANT
	 	 	 
	 	By:	/s/
    Pamela G. Marrone
	 		Pamela
    G. Marrone 

 

    	 

    	 

    

 

Exhibit
A

 

INITIAL
SCOPE OF SERVICES

 

***Exhibit 10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This Securities Purchase Agreement (this “Agreement”)
is dated as of March 13,2020 (the “Effective Date”) by and among IWeb Inc., a Nevada corporation (the “Company”),
and ___________ being a Hong Kong Citizen with the Hong Kong ID number of ___________ with registered address at___________ (including
his successors and assigns, the “Purchaser”).

  

RECITALS

 

WHEREAS, subject
to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section
5 of the Securities Act contained in Section 4(a)(2) thereof and/or Regulations S thereunder, the Company desires to issue and
sell to the Purchaser, and the Purchaser desires to purchase from the Company, certain securities of the Company as more fully
described in this Agreement.

 

NOW, THEREFORE,
IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

ARTICLE I.

DEFINITIONS

 

1.1           
Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings
set forth in this Section 1.1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in, and construed, under Rule 405 under the Securities Act.

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.

 

“Closing”
means the closing of the purchase and sale of the Shares pursuant to Section 2.1.

 

“Closing
Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii)
the Company’s obligations to deliver the Shares, in each case, have been satisfied or waived, but in no event later than
April 30, 2020.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.

 

“DWAC”
shall have the meaning ascribed to such term in Section 2.2(a)(ii).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

    	 	1	 

     

    

 

“Exchange
Rules” shall mean the listing rules of The OTCQB Marketplace.

 

“Liens”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

“Per
Share Purchase Price” equals $2.00 per share of Common Stock, subject to adjustment for reverse and forward stock splits,
stock combinations and other similar transactions of the Common Stock that may occur after the date of this Agreement.

 

“Person”
means an individual, corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(c).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(f).

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Securities
Laws” means, collectively, the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley”), the Securities
Act, the Exchange Act, the Rules and Regulations, the auditing principles, rules, standards and practices applicable to auditors
of “issuers” (as defined in Sarbanes-Oxley) promulgated or approved by the Public Company Accounting Oversight Board,
the Exchange Rules and applicable state securities laws and regulations.

 

“Shares”
means an aggregate of __________ shares of Common Stock to be issued to the Purchasers pursuant to this Agreement (the “Shares”).

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include the location and/or reservation of borrowable shares of Common Stock).

 

“Subscription
Amount” means, an aggregate amount of $_____ to be paid for Shares purchased by the Purchaser in Hong Kong Dollars at
an exchange rate of $1 for HK$7.8 and in immediately available funds.

 

“Subsidiary”
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the OTCQB or NASDAQ (or any successors to any of the foregoing).

 

    	 	2	 

     

    

 

“Transaction
Documents” means this Agreement, and any other documents or agreements executed between the Company and the Purchaser
in connection with the transactions contemplated hereunder.

 

“Transfer
Agent” means Action Stock Transfer, the current transfer agent of the Company, with a mailing address of 2469 E. Fort
Union Blvd., Suite 214, Salt Lake City, Utah 84121, and any successor transfer agent of the Company.

 

ARTICLE II.

PURCHASE AND SALE

 

2.1          
Closing. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent
with the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchaser agrees to
purchase, up to an aggregate of $____. Upon receiving the Purchaser’s Subscription Amount on the Closing Date and the delivery
by the Company and the Purchaser of the other items set forth in Section 2.2 deliverable at the Closing, the Company shall deliver
to the Purchaser his Shares as determined pursuant to Section 2.2(a).

 

2.2           
Deliveries.

 

(a)           
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to the
Purchaser each of the following:

 

(i)               this
Agreement duly executed by the Company;

 

(ii)             subject
to the last sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent
to deliver on an expedited basis via paper Stock Certificate or The Depository Trust Company Deposit or Withdrawal at Custodian
system (“DWAC”) Shares equal to the Purchaser’s Subscription Amount divided by the Per Share Purchase
Price, registered in the name of the Purchaser.

 

(b)           
On or prior to the Closing Date, the Purchaser shall deliver or cause to be delivered to the
Company, as applicable, the following:

 

(i)              
this Agreement duly executed by the Purchaser; and

 

(ii)             
the Purchaser’s Subscription Amount by wire transfer to the bank account directed by
the Company.

 

2.3           
Closing Conditions.

 

(a)       The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

 

(i)              
the accuracy when made and on the Closing Date of the representations and warranties of the
Purchaser contained herein (unless as of a specific date therein in which case they shall be accurate as of such date); 

 

(ii)             
all obligations, covenants and agreements of the Purchaser required to be performed at or
prior to the Closing Date shall have been performed; and

 

(iii)            
the delivery by the Purchaser of the items set forth in Section 2.2(b) of this Agreement on
or prior to the Closing Date.

 

    	 	3	 

     

    

 

(b)           
The respective obligations of the Purchaser hereunder in connection with the Closing are subject
to the following conditions being met:

 

(i)             
the accuracy when made and on the Closing Date of the representations and warranties of the
Company contained herein (unless as of a specific date therein in which case they will be accurate as of such date); 

 

(ii)             
all obligations, covenants and agreements of the Company required to be performed at or prior
to the Closing Date shall have been performed; 

 

(iii)            
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement on
or prior to the Closing Date; and

 

(iv)           
there shall have been no material adverse effect with respect to the Company since the date
hereof.

 

ARTICLE III.

REPRESENTATIONS AND WARRANTIES

 

3.1          
Representations and Warranties of the Company. Except as indicated in the SEC Reports, the Company hereby represents
and warrants to the Purchaser as of the date of this Agreement and as of the Closing Date as follows:

 

(a)            Organization
and Qualification. The Company and each of the Subsidiaries, if any, is an entity duly incorporated or otherwise organized
and validly existing under the laws of each jurisdiction in which it owns or leases properties or conducts any business so as to
require such qualification, with the requisite power and authority to own and use its properties and assets and to carry on its
business as currently conducted.

 

(b)            Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, the Board of Directors or the Company’s stockholders in connection herewith
or therewith other than in connection with the Required Approvals (as defined below).

 

(c)            Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any Governmental Authority or any court or other federal, state, local or other governmental
authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents
or the offer, issue and sale of the Shares, other than: (i) the disclosure filings required for this Agreement, (ii) such filings
as are required to be made under applicable state securities laws, and (iii) such consents, waivers and authorizations that shall
be obtained prior to the Closing (collectively, the “Required Approvals”).

 

    	 	4	 

     

    

 

(d)            Authorization
of the Shares; Registration. The Shares to be sold by the Company and their issue and sale are duly authorized and, when issued
and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and free and
clear of all Liens imposed by the Company.

 

(e)            Capitalization.
Except as may be described in the SEC Reports, all of the issued share capital of the Company has been duly and validly authorized
and issued, is fully paid and non-assessable.

 

(f)             SEC
Reports. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company
under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding
the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, any such documents voluntarily filed by the Company with the Commission, including the exhibits thereto, documents incorporated
by reference therein, being collectively referred to herein as the “SEC Reports”).

 

(g)            Investment
Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not
be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

3.2           
Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants as of the date
hereof and as of the Closing Date to the Company as follows (unless as made of a specific date stated therein, in which case they
shall be accurate as of such date):

 

(a) 
Organization; Authority. The Purchaser is either an individual or an entity duly incorporated
or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full
right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions
contemplated by the Transaction Documents and otherwise to carry out his obligations hereunder and thereunder. The execution and
delivery of the Transaction Documents and performance by the Purchaser of the transactions contemplated by the Transaction Documents
have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable,
on the part of the Purchaser. Each Transaction Document to which he is a party has been duly executed by the Purchaser, and when
delivered by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of the
Purchaser, enforceable against him in accordance with its terms, except: (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’
rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

 

(b) 
Understandings or Arrangements. The Purchaser is acquiring the Shares for his own account
and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution
of the Shares (this representation and warranty not limiting the Purchaser’s right to sell the Shares in compliance with
applicable federal and state securities laws). The Purchaser is acquiring the Shares as principal, not as nominee or agent, and
not with a view to or for distributing or reselling the Shares or any part thereof in violation of the Securities Act or any applicable
state securities law.

 

(c) 
Foreign Investors. The Purchaser hereby represents
that he has satisfied himself as to the full observance by the Purchaser of the laws of its
jurisdiction applicable to the Purchaser in connection with the purchase of the Shares or the
execution and delivery by the Purchaser of this Agreement and the Transaction Documents, including (i) the legal requirements
within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to the purchase,
(iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences,
if any, that may be relevant to the Purchaser’s purchase, holding, redemption, sale,
or transfer of the Shares. The Purchaser’s subscription and payment for, and continued
beneficial ownership of, the Shares will not violate any securities or other laws of the Purchaser’s
jurisdiction applicable to the Purchaser.

 

    	 	5	 

     

    

 

(d) 
Experience of Purchaser. The Purchaser, either alone or together with his representatives,
has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits
and risks of the prospective investment in the Shares, and has so evaluated the merits and risks of such investment. The Purchaser
is able to bear the economic risk of an investment in the Shares and, at the present time, is able to afford a complete loss of
such investment.

 

(e) 
Access to Information. The Purchaser acknowledges that he has had the opportunity to
review the Transaction Documents and the SEC Reports and has been afforded (i) the opportunity to ask such questions as he has
deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering
of the Shares and the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial
condition, results of operations, business, properties, management and prospects sufficient to enable him to evaluate his investment;
and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable
effort or expense that is necessary to make an informed investment decision with respect to the investment.  

 

(f)  
Regulation S. The Purchaser is a non-U.S. person (as such term is defined in Rule 902
of Regulation S under the Securities Act) and is not acquiring the Shares for the account or benefit of a U.S. person. The Purchaser
will not, within six (6) months of the date of the transfer of the Shares to the Purchaser, (i) make any offers or sales of the
Shares in the United States or to, or for the benefit of, a U.S. person (in each case, as defined in Regulation S) other than in
accordance with Regulation S or another exemption from the registration requirements of the Securities Act, or (ii) engage in hedging
transactions with regard to the Shares unless in compliance with the Securities Act. Neither the Purchaser nor any of the Purchaser’s
Affiliates or any person acting on his/her or their behalf has engaged or will engage in directed selling efforts (within the meaning
of Regulation S) with respect to the Shares, and all such persons have complied and will comply with the offering restriction requirements
of Regulation S in connection with the offering of the Shares outside of the United States. Neither the Purchaser nor any person
acting on his behalf has undertaken or carried out any activity for the purpose of, or that could reasonably be expected to have
the effect of, conditioning the market in the United States, its territories or possessions, for any of the Purchaser’s Shares.
The Purchaser agrees not to cause any advertisement of the Purchaser’s Shares to be published in any newspaper or periodical
or posted in any public place and not to issue any circular relating to the Purchaser’s Shares, except such advertisements
that include the statements required by Regulation S, and only offshore and not in the U.S. or its territories, and only in compliance
with any local applicable securities laws. Further, any such sale of the Purchaser’s Shares in any jurisdiction outside of
the United States will be made in compliance with the securities laws of such jurisdiction. The Purchaser will not offer to sell
or sell the Purchaser’s Shares in any jurisdiction unless the Purchaser obtains all required consents, if any.

 

(g) 
Certain Transactions and Confidentiality. Other than consummating the transactions
contemplated hereunder, the Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with the
Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company
during the period commencing as of the time that the Purchaser first discussed the transaction with the Company or any other Person
representing the Company setting forth the material terms of the transactions contemplated hereunder and ending on the Closing
of the transaction contemplated by this Agreement. The Purchaser has maintained the confidentiality of all disclosures made to
him in connection with this transaction (including the existence and terms of this transaction).

 

    	 	6	 

     

    

 

(h) 
No Registration. The Purchaser understands that the Shares have not been, and will
not be, registered under the Securities Act or applicable securities laws of any state or country and therefore the Shares cannot
be sold, pledged, assigned or otherwise disposed of unless they are subsequently registered under the Securities Act and applicable
state securities laws or exemptions from such registration requirements are available. The Company shall be under no obligation
to register the Shares under the Securities Act and applicable state securities laws, and any such registration shall be in the
Company’s sole discretion.

 

(i)   
No General Solicitation. The Purchaser is not purchasing the Shares as a result of
any advertisement, article, notice or other communication regarding the Shares published in any newspaper, magazine or similar
media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

 

(j)       Brokers
or Finders.  The Purchaser has not engaged any brokers, finders or agents, and the Company has not, nor will, incur, directly
or indirectly, as a result of any action taken by the Purchaser, any liability for brokerage or finders’ fees or agents’
commissions or any similar charges in connection with this Agreement.

 

ARTICLE IV.

OTHER AGREEMENTS OF THE PARTIES

 

4.1          
Reservation of Securities. As of the date hereof, the Company has reserved and the Company shall continue to reserve
and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for issuance pursuant
to the Transaction Documents in such amount as may then be required to fulfill its obligations in full under the Transaction Documents.

 

4.2           
Certain Transactions and Confidentiality. The Purchaser covenants that neither he nor any Affiliate acting on his
behalf or pursuant to any understanding with he will execute any purchases or sales, including Short Sales of any of the Company’s
securities during the period commencing with the execution of this Agreement and ending at the Closing of the transaction contemplated
by this Agreement.  The Purchaser also covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company, the Purchaser will maintain the confidentiality of the existence
and terms of this transaction.

 

4.3            
Legends. The Shares may only be disposed of in compliance with state and federal securities laws. In connection with
any transfer of Shares other than pursuant to an effective registration statement or Rule 144, the Company may require the transferor
thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the
form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not
require registration of such transferred Shares under the Securities Act. The Purchaser agrees to the imprinting, so long as is
required by this Section 4.3, of a legend on all of the certificates evidencing the Shares in the following form:

 

THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS.

 

THESE SECURITIES ARE BEING
OFFERED TO INVESTORS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE
SECURITIES ACT”)) AND WITHOUT REGISTRATION WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES
ACT IN RELIANCE UPON REGULATION S PROMULGATED UNDER THE SECURITIES ACT. TRANSFER OF THESE SECURITIES IS PROHIBITED, EXCEPT IN ACCORDANCE
WITH THE PROVISIONS OF REGULATION S PROMULGATED UNDER THE SECURITIES ACT, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT, OR
PURSUANT TO AVAILABLE EXEMPTION FROM REGISTRATION.  HEDGING TRANSACTIONS MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH
THE SECURITIES ACT.

 

The
Purchaser agrees that he will sell any Shares pursuant to either the registration requirements of the Securities Act, including
any applicable prospectus delivery requirements, or an exemption therefrom, and that if Shares are sold pursuant to a registration
statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of
the restrictive legend from certificates representing Shares as set forth in this Section 4.3 is predicated upon the Company’s
reliance upon this understanding.

 

    	 	7	 

     

    

 

ARTICLE V

MISCELLANEOUS

5.1              Termination. 
This Agreement may be terminated by the Company by written notice to the other party if the Closing has not been consummated on
or before April 30, 2020; provided, however, that no such termination will affect the right of any party to sue for
any breach by any other party (or parties).

 

5.2              Fees
and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its/his advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement.

 

5.3              Entire
Agreement. The Transaction Documents, together with the exhibits contain the entire understanding of the parties with respect
to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to
such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

5.4              Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile or email at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date
of transmission, if such notice or communication is delivered via facsimile or email on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

 

    	 	8	 

     

    

 

5.5             Amendments;
Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and the Purchaser or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this
Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any
manner impair the exercise of any such right.

 

5.6             Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

5.7              Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. No party hereto may assign this Agreement or any rights or obligations hereunder without the prior written consent of
the Company and the Purchaser.

 

5.8              No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in this Section 5.8.

 

5.9              Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of Nevada, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its/his respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the Clark County, Nevada. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in Clark County, Nevada, for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement
of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it/he is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper
or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it/him under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of the Transaction Documents, the prevailing party in such action, suit or proceeding
shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with such
action or proceeding.

 

5.10            Survival.
The representations and warranties contained herein shall survive the Closing and the delivery of the Shares. The terms of this
Article V shall survive the termination of the Agreement pursuant to Section 5.1.

 

5.11            Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

 

    	 	9	 

     

    

 

5.12            Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable

 

5.13            Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Purchaser
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages
may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents
and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy
at law would be adequate.

 

5.14           Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

5.15            Construction.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock combinations and other similar transactions of the Common Stock that occur after the date of this
Agreement. The English version of this Agreement, regardless of whether a translation in any other language is or will be made,
shall be the only authentic version.

 

5.16           WAIVER
OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 

 

(Signature Pages Follow)

 

    	 	10	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

 

	
        COMPANY

         

        IWEB INC.

         

        Address for Notice:

        121/34, RS Tower, 8th Floor

        Ratchadaphisek Road, Din Daeng Sub-district, din Daeng

        District,
        Bangkok, Thailand

        TEL: +662-248-2436

        Email:________________

         

         
	 
	
         

         

         

         

        By:__________________________________________

        Name: Ratanaphon Wongnapachant

        Title: Chief Executive Officer and Chairman

         

         
	 

 

 

 

Purchaser

 

 

 

 

 

By:____________________________________________

Name:

Address:

Tel:

Fax:

Email:

 

    	 	11	 

     

    

 

Schedule of Purchasers of Securities
Purchase Agreements

 

	No.	Name of Purchasers	Shares	US$ Amount
	1	Lai Shan MAK	12,820	25,640
	2	Chan Mei Mei	10,000	20,000
	3	Hung Che Leung	10,000	20,000
	4	Wong Yean Shang	30,000	60,000
	5	Ho King Chi Roy	12,820	25,640
	6	Shum Lap Chi	10,000	20,000
	7	Siu Oi Fung	10,000	20,000
	8	Lam Ka Lo Carol	12,820	25,640
	Total	 	108,460	216,920

 

    	 	12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]